SEC Form SC 13G/A filed by Biomea Fusion Inc. (Amendment)

2/9/24 8:35:54 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BMEA alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 BIOMEA FUSION INC COMMON STOCK Cusip #09077A106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #09077A106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,355,690 Item 6: 0 Item 7: 5,355,867 Item 8: 0 Item 9: 5,355,867 Item 11: 14.999% Item 12: HC Cusip #09077A106 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 5,355,867 Item 8: 0 Item 9: 5,355,867 Item 11: 14.999% Item 12: IN Item 1(a). Name of Issuer: BIOMEA FUSION INC Item 1(b). Address of Issuer's Principal Executive Offices: 900 MIDDLEFIELD ROAD, 4th Floor Redwood City, CA 94063 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 09077A106 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 5,355,867 (b) Percent of Class: 14.999% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 5,355,867 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of BIOMEA FUSION INC. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of BIOMEA FUSION INC, amounted to 2,190,024 shares or 6.133% of the total outstanding COMMON STOCK at December 29, 2023. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company * BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of BIOMEA FUSION INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $BMEA alert in real time by email

Recent Analyst Ratings for

$BMEA

Date	Price Target	Rating	Analyst
10/9/2024	$128.00	Buy	Edward Jones
9/27/2024	$18.00	Neutral → Buy	Rodman & Renshaw
9/27/2024	$54.00	Hold → Buy	Truist
8/29/2024	$25.00	Overweight	CapitalOne
6/11/2024		Buy → Hold	Truist
6/7/2024	$30.00 → $5.00	Overweight → Equal Weight	Barclays
4/2/2024	$51.00 → $14.00	Overweight → Neutral	JP Morgan
2/6/2024	$55.00	Buy	Truist

More analyst ratings

SEC Form SC 13G/A filed by Biomea Fusion Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $BMEA

$BMEA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

Amendment: SEC Form SC 13G/A filed by Biomea Fusion Inc.

SEC Form SC 13G filed by Biomea Fusion Inc.

$BMEA SEC Filings

SEC Form 10-Q filed by Biomea Fusion Inc.

Biomea Fusion Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEF 14A filed by Biomea Fusion Inc.

$BMEA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Hitchcock Michael J.M. bought $100,600 worth of shares (10,000 units at $10.06), increasing direct ownership by 200% to 15,000 units (SEC Form 4)

Chief Financial Officer Valle Franco was granted 4,448 shares and bought $55,361 worth of shares (12,509 units at $4.43), increasing direct ownership by 66% to 42,500 units (SEC Form 4)

$BMEA Press Releases

Fastest customizable press release news feed in the world

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

$BMEA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Interim CEO Hitchcock Michael J.M.

Chief Financial Officer Valle Franco was granted 495 shares, increasing direct ownership by 1% to 42,995 units (SEC Form 4)

Director Hitchcock Michael J.M. bought $100,600 worth of shares (10,000 units at $10.06), increasing direct ownership by 200% to 15,000 units (SEC Form 4)

$BMEA Leadership Updates

Live Leadership Updates

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Biomea Fusion Announces Leadership Transition

$BMEA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Edward Jones initiated coverage on Biomea Fusion with a new price target

Biomea Fusion upgraded by Rodman & Renshaw with a new price target

Biomea Fusion upgraded by Truist with a new price target

$BMEA Financials

Live finance-specific insights

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Recent Analyst Ratings for
$BMEA

$BMEA
Large Ownership Changes

$BMEA
SEC Filings

$BMEA
Insider Purchases

$BMEA
Press Releases

$BMEA
Insider Trading

$BMEA
Leadership Updates

$BMEA
Analyst Ratings

$BMEA
Financials